Improving Outcomes in State AIDS Drug Assistance Programs

    loading  Checking for direct PDF access through Ovid



State AIDS Drug Assistance Programs (ADAPs) provide antiretroviral medications to patients with no access to medications. Resource constraints limit the ability of many ADAPs to meet demand for services.


To determine ADAP eligibility criteria that minimize morbidity and mortality and contain costs.


We used Discrete Event Simulation to model the progression of HIV-infected patients and track the utilization of an ADAP. Outcomes included 5-year mortality and incidence of first opportunistic infection or death and time to starting antiretroviral therapy (ART). We compared expected outcomes for 2 policies: (1) first-come first-served (FCFS) eligibility for all with CD4 count ≤350/μL (current standard) and (2) CD4 count prioritized eligibility for those with CD4 counts below a defined threshold.


In the base case, prioritizing patients with CD4 counts ≤250/μL led to lower 5-year mortality than FCFS eligibility (2.77 vs. 3.27 deaths per 1000 person-months) and to a lower incidence of first opportunistic infection or death (5.55 vs. 6.98 events per 1000 person-months). CD4-based eligibility reduced the time to starting ART for patients with CD4 counts ≤200/μL. In sensitivity analyses, CD4-based eligibility consistently led to lower morbidity and mortality than FCFS eligibility.


When resources are limited, programs that provide ART can improve outcomes by prioritizing patients with low CD4 counts.

Related Topics

    loading  Loading Related Articles